2026.11.22 (일)

  • 맑음속초2.7℃
  • 구름많음-4.5℃
  • 맑음철원-4.3℃
  • 맑음동두천-1.8℃
  • 흐림파주-3.0℃
  • 맑음대관령-5.0℃
  • 구름많음춘천-3.8℃
  • 맑음백령도6.9℃
  • 맑음북강릉2.5℃
  • 맑음강릉4.0℃
  • 맑음동해-0.2℃
  • 구름많음서울0.9℃
  • 구름많음인천3.4℃
  • 맑음원주-1.9℃
  • 맑음울릉도4.6℃
  • 맑음수원0.4℃
  • 맑음영월-3.7℃
  • 맑음충주-3.1℃
  • 맑음서산1.9℃
  • 맑음울진3.6℃
  • 맑음청주2.4℃
  • 맑음대전0.4℃
  • 맑음추풍령-3.0℃
  • 맑음안동-1.8℃
  • 맑음상주-1.4℃
  • 맑음포항2.5℃
  • 맑음군산1.1℃
  • 맑음대구0.4℃
  • 맑음전주1.4℃
  • 맑음울산0.8℃
  • 맑음창원3.7℃
  • 맑음광주3.2℃
  • 맑음부산4.9℃
  • 맑음통영4.2℃
  • 맑음목포5.2℃
  • 맑음여수5.4℃
  • 맑음흑산도6.2℃
  • 맑음완도4.1℃
  • 맑음고창0.7℃
  • 맑음순천-2.0℃
  • 맑음홍성(예)0.1℃
  • 맑음-1.5℃
  • 맑음제주7.0℃
  • 맑음고산7.1℃
  • 맑음성산4.0℃
  • 맑음서귀포7.4℃
  • 맑음진주-0.8℃
  • 구름많음강화2.5℃
  • 맑음양평-1.5℃
  • 맑음이천-2.3℃
  • 맑음인제-4.3℃
  • 맑음홍천-3.3℃
  • 맑음태백-3.2℃
  • 맑음정선군-3.8℃
  • 맑음제천-5.7℃
  • 맑음보은-3.0℃
  • 맑음천안-2.0℃
  • 맑음보령4.5℃
  • 맑음부여-0.9℃
  • 맑음금산-1.6℃
  • 맑음-0.1℃
  • 맑음부안1.6℃
  • 맑음임실-1.6℃
  • 맑음정읍0.4℃
  • 맑음남원-0.5℃
  • 맑음장수-2.8℃
  • 맑음고창군0.7℃
  • 맑음영광군1.0℃
  • 맑음김해시2.2℃
  • 맑음순창군-0.9℃
  • 맑음북창원2.2℃
  • 맑음양산시0.5℃
  • 맑음보성군1.1℃
  • 맑음강진군1.0℃
  • 맑음장흥-0.6℃
  • 맑음해남0.5℃
  • 맑음고흥-0.6℃
  • 맑음의령군-2.2℃
  • 맑음함양군-2.3℃
  • 맑음광양시3.3℃
  • 맑음진도군1.2℃
  • 맑음봉화-6.1℃
  • 맑음영주-3.1℃
  • 맑음문경-1.6℃
  • 맑음청송군-5.2℃
  • 맑음영덕3.3℃
  • 맑음의성-3.2℃
  • 맑음구미-1.2℃
  • 맑음영천-2.1℃
  • 맑음경주시-2.1℃
  • 맑음거창-2.6℃
  • 맑음합천-0.6℃
  • 맑음밀양-0.7℃
  • 맑음산청-0.8℃
  • 맑음거제2.2℃
  • 맑음남해4.1℃
  • 맑음0.6℃
기상청 제공
Shoppy 로고
GI CELL Enters Agreement with Optieum Biotechnologies
  • 해당된 기사를 공유합니다

GI CELL Enters Agreement with Optieum Biotechnologies

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan).

Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will carry out feasibility studies and be responsible for further development and commercialization of the CAR-NK cell products if the company exercises an option. For each option exercised, Optieum Biotechnologies will be entitled to an option-exercise fee, development and commercial milestone payments, as well as single-digit royalties on sales.

“We are pleased to enter this collaboration with Optieum Biotechnologies as we continue unlocking the full potential of our NKPURE Expander® platform,” said Dr. Chun Pyo Hong, CEO of GI CELL. “We look forward to evaluating the scFv antibodies from Optieum Biotechnologies’ discovery platform, which have the potential to accelerate the development of our novel CAR-NK cells.”

“We have been dedicated to expanding the toolbox to enable immune cell-based therapies in cancer treatment, through our proprietary Eumbody System™. Optieum Biotechnologies’ strength in discovery of functional and improved scFvs in conjunction with GI CELL’s expertise in NK cell engineering and manufacturing may lead to a generation of promising cellular immunotherapy for unmet medical needs,” said Shun Nishioka, CEO of Optieum Biotechnologies.

About GI CELL

GI CELL is a biotechnology company that drives research and development of novel immune cell-based therapies with innovative technologies. Using its proprietary Immune CellPURE Expander® platform for highly potent NK and T cell development, GI CELL has integrated its ancillary material screening and cell expansion technologies to streamline the entire cell product development process. The Company is advancing its allogenic NK cell therapies to transform the treatment paradigm for patients with hematological malignancies and solid tumors. GI CELL has multiple NK cell product candidates in IND-enabling and preclinical development.

About Optieum Biotechnologies

Optieum Biotechnologies is a biotechnology company with a platform engine to elicit functional and improved scFvs for CAR-T cell and CAR-NK therapies with superior anti-tumor toxicity and persistence. Optieum Biotechnologies’ scFv generation platform, Eumbody System, enables to acquire the scFv from the CAR-T cell’s functionality perspective rather than conventional binding affinity approach. The company is advancing multiple CAR-T cell product candidates targeting hematological malignancies and solid tumors which demonstrate significantly improved anti-tumor toxicity, proliferation capacity and mitigated antigen depletion.

언론연락처: GI CELL, Inc. Heehyoung Lee, PhD EVP, BD and Corporate Strategy or

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기